UniProt Q9NRM7 · PDB · AlphaFold · Substrate: SGKtide · Clone: Catalytic (aa480-1088)medium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Capivasertib | 96.2% | 3.8% | 96.48 | 0.644 |
| 2 | Netarsudil | 92.3% | 7.7% | 93.22 | 0.676 |
| 3 | Midostaurin | 90.9% | 9.1% | 78.64 | 0.500 |
| 4 | Ponatinib | 78.9% | 21.1% | 78.23 | 0.534 |
| 5 | Defactinib | 74.8% | 25.2% | 92.68 | 0.450 |
| 6 | Sunitinib | 71.0% | 29.0% | 91.73 | 0.524 |
| 7 | Gilteritinib | 65.8% | 34.2% | 88.97 | 0.506 |
| 8 | Pacritinib | 62.9% | 37.1% | 88.64 | 0.452 |
| 9 | Baricitinib | 58.9% | 41.1% | 97.99 | 0.616 |
| 10 | Fostamatinib | 56.4% | 43.6% | 96.74 | 0.613 |
| 11 | Neratinib | 40.6% | 59.4% | 93.18 | 0.597 |
| 12 | Brigatinib | 39.5% | 60.5% | 82.96 | 0.513 |
| 13 | Vemurafenib | 38.9% | 61.1% | 96.49 | 0.598 |
| 14 | Darovasertib | 37.5% | 62.5% | 96.99 | 0.719 |
| 15 | Ruxolitinib | 35.2% | 64.8% | 98.25 | 0.592 |
| 16 | Fedratinib | 24.7% | 75.3% | 96.21 | 0.576 |
| 17 | Ripretinib | 24.2% | 75.8% | 92.95 | 0.674 |
| 18 | Nintedanib | 21.2% | 78.8% | 90.23 | 0.608 |
| 19 | Pralsetinib | 18.7% | 81.3% | 93.43 | 0.643 |
| 20 | Bosutinib | 18.0% | 82.0% | 87.22 | 0.555 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 3.51
- Epithelial log2(TPM+1): 2.14
- Fold change: 1.37
- Status: Upregulated
High-confidence drugs
- Netarsudil — inh 92.3% · KISS 34.94
- Midostaurin — inh 90.9% · KISS 20.60
- Ponatinib — inh 78.9% · KISS 10.22
Selectivity landscape vs inhibition on LATS2
Each point is one of the 92 approved drugs; color = inhibition % on LATS2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…